IN BRIEF: Abcam expects increased revenue on strong product demand

Abcam PLC - Cambridge, England-based life science research tools - Expects full-year 2021 revenue ...

Alliance News 27 January, 2022 | 2:51PM
Email Form Facebook Twitter LinkedIn RSS

Abcam PLC - Cambridge, England-based life science research tools - Expects full-year 2021 revenue of GBP315 million, up 17% from GBP269.3 million the year before.

Notes that this includes a GBP2.5 million contribution of incremental revenue from BioVision, following the acquisition's completion on October 27.

Attributes the revenue growth to strong demand for its proprietary products, with in-house catalogue sales up approximately 37%.

Adds that the continued recovery in global lab activity also lifted its results.

"2021 was a year of significant innovation and growth in proteomic tools and discovery," Chief Executive Alan Hirzel comments.

Current stock price: 1,281.00 pence, up 0.6%

12-month change: down 23%

By Abby Amoakuh; abbyamoakuh@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Abcam PLC

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures